STRO Company Profile and Key Details

Q: Who are the executives of STRO?

Dr. Nicki Vasquez Ph.D.Chief Portfolio Strategy & Alliance OfficerMs. Linda A. FitzpatrickChief People & Communications OfficerMr. David Pauling J.D., M.A.Gen. CounselDr. Shabbir T. AnikChief Technical Operations OfficerMs. Jane Chung R.Ph.Chief Commercial OfficerDr. James R. Swartz Ph.D., Sc.D.FounderMs. Annie J. Chang M.B.A.Vice President of Investor RelationsMr. William J. Newell J.D.Chief Executive Officer & DirectorMr. Edward C. AlbiniChief Financial Officer & Sec.Dr. Trevor J. HallamPres of Research & Chief Scientific OfficerMs. Brunilda Shtylla M.B.A., M.S.Chief Bus. OfficerDr. Venkatesh Srinivasan Ph.d.Chief Technical Operations OfficerDr. Trevor J. Hallam Ph.D.Pres of Research & Chief Scientific Officer

NASDAQ : STRO

Sutro Biopharma

$12.23

0.48+4.09%

At Close 4:00 PM

57.9

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Sutro Biopharma, Inc. (STRO) stock surged +4.09%, trading at $12.23 on NASDAQ, up from the previous close of $11.75. The stock opened at $12.19, fluctuating between $11.88 and $13.26 in the recent session.

Stock Snapshot

11.75

Prev. Close

104.12M

Market Cap

11.88

Day Low

-0.47

P/E Ratio

-26

EPS (TTM)

-1.9

Cash Flow per Share

12.19

Open

8.51M

Number of Shares

13.26

Day High

79.2%

Free Float in %

2.45

Book Value

204.68K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jan 09, 2026	11.93	13.30	11.88	12.23	204.29K
Jan 08, 2026	11.70	11.99	11.14	11.75	155.92K
Jan 07, 2026	11.40	12.32	11.24	11.75	123.98K
Jan 06, 2026	10.78	11.52	10.78	11.52	67.71K
Jan 05, 2026	10.95	11.59	10.15	10.87	65.87K
Jan 02, 2026	11.50	11.74	10.60	10.96	69.89K
Dec 31, 2025	11.71	12.18	11.47	11.57	113.38K
Dec 30, 2025	11.12	11.90	11.03	11.67	144.36K
Dec 29, 2025	11.28	11.36	11.00	11.10	101.39K
Dec 26, 2025	10.73	12.00	10.73	11.49	106.47K
Dec 24, 2025	10.35	10.83	10.20	10.75	40.23K
Dec 23, 2025	10.31	10.61	10.09	10.38	49.53K
Dec 22, 2025	9.83	11.09	9.72	10.37	88.9K
Dec 19, 2025	8.94	10.15	8.49	9.98	320.15K
Dec 17, 2025	9.95	9.95	8.77	9.13	88.9K
Dec 16, 2025	9.90	10.09	9.63	9.81	99.12K
Dec 15, 2025	9.79	10.10	9.53	9.93	63.66K
Dec 12, 2025	9.78	10.10	9.53	9.83	121.57K
Dec 11, 2025	8.92	9.82	8.79	9.81	86.17K
Dec 10, 2025	8.38	9.17	8.23	9.00	127.61K

Contact Details

South San Francisco, CA 94080

United States

https://www.sutrobio.com 650 881 6500

About Company

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Stock Peers

REGN

-4.46-0.56%

Regeneron Pharmaceuticals, Inc.$796.55 ARGX

-7.07997-0.89%

argenx SE$788.49 MDGL

-42.16-7.58%

Madrigal Pharmaceuticals, Inc.$514.06 UTHR

-7.6-1.55%

United Therapeutics Corporation$483.23 VRTX

-5.82-1.24%

Vertex Pharmaceuticals Incorporated$463.86 ALNY

-1.11-0.28%

Alnylam Pharmaceuticals, Inc.$398.29 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

-5.93-2.01%

Praxis Precision Medicines, Inc.$288.45 KRYS

12.5+5.02%

Krystal Biotech, Inc.$261.41 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

Sutro Biopharma, Inc. (NASDAQ:STRO) closed at $12.23 USD, gaining $0.48 (4.09%) from the previous close of $11.75. The stock is currently mid-range between its 52-week high and low $5.20 and $21.50. With a market capitalization of about $104.12 million, Sutro Biopharma, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.53). Key stats such as the average daily volume over the past year has been around 127.57 thousand shares, trading with heavier-than-usual volume. Headquartered in South San Francisco, CA, Sutro Biopharma, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jane Chung, the company employs approximately 269 people and listed since September 27, 2018. Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 14.39%, SMA50 26.02%, SMA200 39.23%). The stock’s 14-day RSI is 66.31 (firm momentum), while the ATR of 0.98 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -43.12% below its high and over 133.8% above its low. Average 10-day trading volume of 114.61 thousand shares is below the 3-month average of 127.96 thousand, indicating normal recent market interest.

Valuation Metrics

Sutro Biopharma, Inc. trades at a P/E ratio of -0.48, slightly below the S&P 500 average, with a price-to-sales ratio of 0.99 and a price-to-book ratio of -1.19 indicating negative book value, which may reflect financial stress. The P/FCF stands at -0.46, also below market averages.

Dividend & Fair Value

Sutro Biopharma, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.76. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Sutro Biopharma, Inc. generated EPS of -$25.98 over the past year. Five-year average earnings growth is -4.05%. Wall Street analysts project EPS growth of 22.64% annually over the next five years. The latest quarter delivered EPS of -$0.67. The next quarter is forecast at -$8.15. Next year's EPS is expected at -$10.56. Analyst sentiment is neutral. Analyst rating data shows there are 1 Strong Buy ratings, 0 Buy ratings, 4 Hold ratings, 0 Sell rating and 2 Strong Sell ratings. Price targets range from $10.00 to $0.80. The high target offers -18.23% upside. The low target suggests -93.46% downside. The mean target is $2.97. This offers -75.72% upside. Sutro Biopharma, Inc. earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by 59.52%. The prior quarter beat by -64.1%. Over the last six quarters, Apple has recorded several small beats. These include -22.37% in August 13, 2024.

Shareholding & Insider Activity

Sutro Biopharma, Inc. has 84.77 million shares outstanding. The public float is 67.12 million shares, elevated short interest at 4.19% of float. This equals 3.53 million shares. The short ratio is 7.36 days. Institutional investors hold 70.19% of the float. Insiders own 4.62%. Merck & Co., Inc. holds 2.72 million shares, Freund John Gordon has 560.05 thousand shares and Chung Jane has 122.85 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Sutro Biopharma generated $153.73M in revenue, or $2.56 per share. Gross margin was 95.57%, operating margin -58.07%, and net profit margin -69.47%. Returns are negative, with ROA at -22.69% and ROE at -71.36%.
On valuation metrics, Sutro Biopharma trades at a P/E of -0.48, P/S of 0.99 and P/B of -1.19. The current ratio is 2.53 and quick ratio is 2.53. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is 13.55 days. Debt-to-equity is -0.20, supported by a cash flow-to-debt ratio of -12.60.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Sutro Biopharma posted revenue of $153.73M, down slightly from $67.77M in the prior quarter. Gross profit was $146.92M (margin 95.57%). Operating income was - $89.28M (margin -58.1%). Net income was- $106.79M (EPS - $1.78).
The company ended the quarter with $375.62M in cash and short-term investments, a total debt of $182.75M, and net debt of $113.48M. Total assets were $470.74M, with equity of $149.65M. Financials further reflected weakness, with operating cash flow of - $111.62M, free cash flow of - $115.93M, and capital expenditures of - $4.32M.

Price Forecast & Outlook

Our AI price prediction model suggests that Sutro Biopharma, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 8.26%, with price expected at $13.24 by January 23, 2026, within a range of $12.67 to $13.81 3-Month Outlook: Projected fall of -24.94%, reaching $9.18 by April 09, 2026, with a range of $8.23 to $9.93. 1-Year Outlook: Projected loss of -26.17%, with price at $9.03 by December 31, 2026, within a range of $0.00 to $2.25.

Key Takeaways

Sutro Biopharma, Inc. (NASDAQ:STRO) shares are flat 1.56% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Sutro Biopharma, Inc. trading at a premium to the broader market with a P/E of -0.48. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $14.34, suggesting 17.25% upside. Our AI forecast model points to short-term strength (8.26% over two weeks), a medium-term fall (-24.94% over three months), and a longer-term loss (-26.17% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Sutro Biopharma, Inc. (STRO) stock price?

Sutro Biopharma, Inc. (NASDAQ: STRO) stock price is $12.23 in the last trading session. During the trading session, STRO stock reached the peak price of $13.26 while $11.88 was the lowest point it dropped to. The percentage change in STRO stock occurred in the recent session was 4.09% while the dollar amount for the price change in STRO stock was $0.48.

STRO's industry and sector of operation?

The NASDAQ listed STRO is part of Biotechnology industry that operates in the broader Healthcare sector. Sutro Biopharma, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of STRO?

Dr. Nicki Vasquez Ph.D.
Chief Portfolio Strategy & Alliance Officer
Ms. Linda A. Fitzpatrick
Chief People & Communications Officer
Mr. David Pauling J.D., M.A.
Gen. Counsel
Dr. Shabbir T. Anik
Chief Technical Operations Officer
Ms. Jane Chung R.Ph.
Chief Commercial Officer
Dr. James R. Swartz Ph.D., Sc.D.
Founder
Ms. Annie J. Chang M.B.A.
Vice President of Investor Relations
Mr. William J. Newell J.D.
Chief Executive Officer & Director
Mr. Edward C. Albini
Chief Financial Officer & Sec.
Dr. Trevor J. Hallam
Pres of Research & Chief Scientific Officer
Ms. Brunilda Shtylla M.B.A., M.S.
Chief Bus. Officer
Dr. Venkatesh Srinivasan Ph.d.
Chief Technical Operations Officer
Dr. Trevor J. Hallam Ph.D.
Pres of Research & Chief Scientific Officer

How STRO did perform over past 52-week?

STRO's closing price is 135.19% higher than its 52-week low of $5.20 where as its distance from 52-week high of $21.50 is -43.12%.

How many employees does STRO have?

Number of STRO employees currently stands at 269.

Link for STRO official website?

Official Website of STRO is: https://www.sutrobio.com

How do I contact STRO?

STRO could be contacted at phone 650 881 6500 and can also be accessed through its website. STRO operates from 111 Oyster Point Boulevard, South San Francisco, CA 94080, United States.

How many shares of STRO are traded daily?

STRO stock volume for the day was 204.68K shares. The average number of STRO shares traded daily for last 3 months was 127.57K.

What is the market cap of STRO currently?

The market value of STRO currently stands at $104.12M with its latest stock price at $12.23 and 8.51M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	269
Beta	1.53
Sales or Revenue	$153.73M
5Y Sales Change%	-0.617%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

STRO Company Profile and Key Details

Sutro Biopharma

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Dividend & Fair Value

Earnings & Analyst Outlook

Company Overview

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Valuation Metrics